Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLK Allakos Inc.

Not Yet Opened 11-21 16:00:00 EST

0.9069

-0.0323

-3.44%

盘后0.9000

-0.0069-0.76%

19:47 EST

High0.9393	Low0.8900	Vol453.13K
Open0.9157	D1 Closing0.9392	Amplitude5.25%
Mkt Cap81.03M	Tradable Cap54.15M	Total Shares89.34M
T/O410.10K	T/O Rate0.76%	Tradable Shares59.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALLK","market":"US","secType":"STK","nameCN":"Allakos Inc.","latestPrice":0.9069,"timestamp":1732222800000,"preClose":0.9392,"halted":0,"volume":453130,"hourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.9069,"latestTime":"19:47 EST","volume":116611,"amount":105752.1158,"timestamp":1732236433767},"delay":0,"floatShares":59710414,"shares":89343634,"eps":-2.024316,"marketStatus":"Not Yet Opened","change":-0.0323,"latestTime":"11-21 16:00:00 EST","open":0.9157,"high":0.939299,"low":0.89,"amount":410096.3028069,"amplitude":0.05249,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.024316,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732266000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1531972800000,"exchange":"NASDAQ","adjPreClose":0.9392,"preHourTrading":{"tag":"盘前","latestPrice":0.95,"preClose":0.9392,"latestTime":"09:07 EST","volume":310,"amount":294.391996,"timestamp":1732198058522},"postHourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.9069,"latestTime":"19:47 EST","volume":116611,"amount":105752.1158,"timestamp":1732236433767},"volumeRatio":0.474431,"impliedVol":1.0283,"impliedVolPercentile":0.1912},"requestUrl":"/m/hq/s/ALLK","defaultTab":"news","newsList":[{"id":"2484798980","title":"Allakos Inc. Alters Lease Agreement for Cost Savings","url":"https://stock-news.laohu8.com/highlight/detail?id=2484798980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484798980?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:23","pubTimestamp":1731968606,"startTime":"0","endTime":"0","summary":"Allakos ( ($ALLK) ) has provided an announcement. Allakos Inc. has entered into a Lease Termination Agreement with its landlord, significantly alte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allakos-inc-alters-lease-agreement-for-cost-savings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allakos-inc-alters-lease-agreement-for-cost-savings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2482407759","title":"All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2482407759","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482407759?lang=en_us&edition=fundamental","pubTime":"2024-11-12 01:00","pubTimestamp":1731344411,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Allakos Inc. , as it has been recently upgraded to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for Allakos is essentially a positive comment on its earnings outlook that could have a favorable impact on its sto","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-allakos-allk-rating-upgrade-170011581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLK"],"gpt_icon":0},{"id":"2481421483","title":"Allakos Inc    expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481421483","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481421483?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:52","pubTimestamp":1731081128,"startTime":"0","endTime":"0","summary":"* Allakos Inc     is expected to show no change in quarterly revenue when it reports  results  for the period ending December 31 2024   *    * LSEG's mean analyst estimate for Allakos Inc is for a los","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Allakos Inc    expected to post a loss of 21 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLK"],"gpt_icon":0},{"id":"2481902531","title":"Allakos Runs Up Into A Near-Term Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902531","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481902531?lang=en_us&edition=fundamental","pubTime":"2024-11-07 18:13","pubTimestamp":1730974423,"startTime":"0","endTime":"0","summary":"Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria.Phase 1 work with intravenous and subcutaneous AK006 demon","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210206680/image_1210206680.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210206680/image_1210206680.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4734177-allakos-runs-up-into-a-near-term-catalyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2481470926","title":"Allakos (ALLK) Gets a Sell from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2481470926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481470926?lang=en_us&edition=fundamental","pubTime":"2024-11-07 16:17","pubTimestamp":1730967447,"startTime":"0","endTime":"0","summary":"Barclays analyst Carter Gould maintained a Sell rating on Allakos (ALLK – Research Report) today and set a price target of $1.00. The company’s sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/allakos-allk-gets-a-sell-from-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/allakos-allk-gets-a-sell-from-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2481945836","title":"Allakos (ALLK) Gets a Hold from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2481945836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481945836?lang=en_us&edition=fundamental","pubTime":"2024-11-07 13:25","pubTimestamp":1730957110,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome maintained a Hold rating on Allakos (ALLK – Research Report) today. The company’s shares closed yesterday at $1.41. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/allakos-allk-gets-a-hold-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/allakos-allk-gets-a-hold-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","TD","BK4139","BK4585","COWN","BK4207","BK4127","ALLK"],"gpt_icon":0},{"id":"2481954142","title":"Allakos Inc Qtrly Net Loss per Basic and Diluted Share Was $0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2481954142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481954142?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:02","pubTimestamp":1730926920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA4BFXXF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2481541219","title":"Allakos Inc: Reiterates That It Expects Restructuring Activities Will Extend Cash Runway Into Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481541219?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:02","pubTimestamp":1730926920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA4BFXXF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2481956798","title":"Allakos Q3 Net Income USD -18.372 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481956798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481956798?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:02","pubTimestamp":1730926920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nPLX0D3049:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2477371453","title":"Allakos Insiders Miss 24% Gain After Offloading Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2477371453","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477371453?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:36","pubTimestamp":1729596999,"startTime":"0","endTime":"0","summary":"Last week, Allakos Inc.'s (NASDAQ:ALLK) stock jumped 24%, but insiders who sold US$88k worth of stock in over the past...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-allk/allakos/news/allakos-insiders-miss-24-gain-after-offloading-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2475388253","title":"Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2475388253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475388253?lang=en_us&edition=fundamental","pubTime":"2024-10-14 14:40","pubTimestamp":1728888015,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allakos (ALLK – Research Report), Edwards Lifescie...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-allakos-allk-edwards-lifesciences-ew-and-newamsterdam-pharma-company-nams?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-allakos-allk-edwards-lifesciences-ew-and-newamsterdam-pharma-company-nams?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4504","BK4567","HCSG","BK4585","IE00BYQQ9H92.USD","ALLK","BK4137","BK4588","EW","NAMS","IE00BFXG0V08.USD","BK4139"],"gpt_icon":0},{"id":"2474601800","title":"TD Cowen Sticks to Their Hold Rating for Allakos (ALLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474601800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474601800?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:46","pubTimestamp":1728647199,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome maintained a Hold rating on Allakos (ALLK – Research Report) today. The company’s shares closed yesterday at $0.66. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-hold-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-hold-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","ALLK"],"gpt_icon":0},{"id":"2474106743","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474106743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474106743?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:30","pubTimestamp":1728646228,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Allakos (ALLK – Research...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-allakos-allk-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-allakos-allk-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ALLK","TPST","HCSG","ALNY","BK4548","BK4139","BK4137","BK4585"],"gpt_icon":0},{"id":"2474606740","title":"LifeSci Capital Reaffirms Their Hold Rating on Allakos (ALLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474606740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474606740?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:30","pubTimestamp":1728646216,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Hold rating on Allakos (ALLK – Research Report) today. The company’s shares closed yesterday at $0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-hold-rating-on-allakos-allk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-hold-rating-on-allakos-allk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK"],"gpt_icon":0},{"id":"2474029061","title":"Piper Sandler Sticks to Its Buy Rating for Allakos (ALLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474029061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474029061?lang=en_us&edition=fundamental","pubTime":"2024-10-11 18:37","pubTimestamp":1728643049,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Allakos (ALLK – Research Report), with a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":"33b45fe74032ec2dd4cb09d28fd79d1f","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-allakos-allk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK"],"gpt_icon":0},{"id":"2474731772","title":"Allakos Subcutaneous Therapy for Mast Cells-Related Diseases 'Well-Tolerated;' Shares Up After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2474731772","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474731772?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:55","pubTimestamp":1728593739,"startTime":"0","endTime":"0","summary":"Allakos  said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was \"well-tolerated with a favorable safety profile.\"The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.Shares of the company were advancing over 7% in extended trading.Price: 0.7076, Change: +0.05, Percent Change: +7.37","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2474715217","title":"BRIEF-Allakos Announces Phase 1 Trial Results Of Subcutaneous Ak006 In Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2474715217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474715217?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:11","pubTimestamp":1728591110,"startTime":"0","endTime":"0","summary":"Allakos Inc   :   * ALLAKOS ANNOUNCES PHASE 1 TRIAL RESULTS OF SUBCUTANEOUS AK006 IN HEALTHY VOLUNTEERS   * ALLAKOS- AK006 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * ALLAKOS INC: TOP-LINE PHASE 1 RESULTS OF INTRAVENOUS AK006 IN PATIENTS WITH CSU ARE EXPECTED IN EARLY Q1 OF 2025Source text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2474797387","title":"Allakos- Ak006 Well-Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2474797387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474797387?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:02","pubTimestamp":1728590520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nTUA9C26DM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLK","BK4139"],"gpt_icon":0},{"id":"2474779733","title":"Allakos Inc: Top-Line Phase 1 Results of Intravenous Ak006 in Patients With Csu Are Expected in Early Q1 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2474779733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474779733?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:02","pubTimestamp":1728590520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nTUA9C26DM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALLK"],"gpt_icon":0},{"id":"2474294779","title":"Allakos Announces Phase 1 Trial Results of Subcutaneous Ak006 in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2474294779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474294779?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:02","pubTimestamp":1728590520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nTUA9C26DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALLK","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allakos.com","stockEarnings":[{"period":"1week","weight":-0.2314},{"period":"1month","weight":-0.3232},{"period":"3month","weight":0.2682},{"period":"6month","weight":-0.3613},{"period":"1year","weight":-0.4727},{"period":"ytd","weight":-0.6678}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.248014},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.072416},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.117765},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.025548},{"month":5,"riseRate":0.333333,"avgChangeRate":0.012634},{"month":6,"riseRate":0.5,"avgChangeRate":-0.038115},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009175},{"month":8,"riseRate":0.571429,"avgChangeRate":0.233613},{"month":9,"riseRate":0.428571,"avgChangeRate":0.016479},{"month":10,"riseRate":0.428571,"avgChangeRate":0.110399},{"month":11,"riseRate":0.714286,"avgChangeRate":0.115748},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.070932}],"exchange":"NASDAQ","name":"Allakos Inc.","nameEN":"Allakos Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allakos Inc.(ALLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allakos Inc.,ALLK,Allakos Inc.股票,Allakos Inc.股票老虎,Allakos Inc.股票老虎国际,Allakos Inc.行情,Allakos Inc.股票行情,Allakos Inc.股价,Allakos Inc.股市,Allakos Inc.股票价格,Allakos Inc.股票交易,Allakos Inc.股票购买,Allakos Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allakos Inc.(ALLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allakos Inc.(ALLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}